Samsung Bioepis

Company snapshot

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therape

• 24 active pipeline program(s) linked via ClinicalTrials.gov.
• 24 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Samsung Bioepis. Not investment advice.

• Peer + 0 momentum

  Chinese Academy of

  TA overlap score 40

• Peer + 0 momentum

  AbbVie Deutschland GmbH

  TA overlap score 40

• Peer + 0 momentum

  Chongqing Precision Biotech

  TA overlap score 40

• Peer + 0 momentum

  Cardiff Oncology

  TA overlap score 31.6

• Peer + 0 momentum

  MEREO BIOPHARMA GROUP

  TA overlap score 29.4

• Peer + 0 momentum

  Revolution Medicines

  TA overlap score 25.2

• Peer + 0 momentum

  Oncolytics Biotech

  TA overlap score 24.6

• Peer + 0 momentum

  CASI Pharmaceuticals

  TA overlap score 24.4

• Peer + 0 momentum

  Apogee Therapeutics

  TA overlap score 21.6

Recent activity

Latest pipeline, patent, and corporate events for Samsung Bioepis.

1. Jun 8, 2026 Clinical update

   SB27-3004 — Phase 3

2. Jun 8, 2026 Clinical update

   SB27-1005 — Phase 1

3. Jun 8, 2026 Clinical update

   E303-1001 — Phase 1

4. Jun 8, 2026 Clinical update

   SSRI treated group — Unknown

5. Jun 8, 2026 Clinical update

   SB11 (Proposed ranibizumab biosimilar) — Phase 3

View all clinical trial activity →

• What is Samsung Bioepis?

  Samsung Bioepis is a pharma organization headquartered in KR. Primary therapeutic focus areas include Colorectal Cancer, Lymphoma, Extranodal NK-T-Cell, Cancer of Stomach, Dyspepsia, Depression. NovaPharmaNews links 24 clinical program(s), 0 drug profile(s), and 0 patent record(s

• Is Samsung Bioepis publicly traded?

  Samsung Bioepis appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Samsung Bioepis develop or market?

  We link 34 drug profile(s) where Samsung Bioepis is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/samsung-bioepis-nl-b-v#company-drugs.

• What are the latest developments for Samsung Bioepis?

  In the last 12 months our linked public records show 24 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Samsung Bioepis focus on?

  Samsung Bioepis focuses on Colorectal Cancer, Lymphoma, Extranodal NK-T-Cell, Cancer of Stomach based on our analysis of their pipeline programs and drug development activities.